Recent Investment Analysts’ Ratings Updates for Elevance Health (ELV)

Several analysts have recently updated their ratings and price targets for Elevance Health (NYSE: ELV):

• 4/29/2026 – Elevance Health was upgraded by Citigroup Inc. to “buy”.
• 4/29/2026 – Elevance Health was upgraded by Bank of America Corporation from “neutral” to “buy”. They now have a $435.00 price target on the stock, up from $405.00.
• 4/28/2026 – Elevance Health had its price target raised by JPMorgan Chase & Co. from $397.00 to $411.00. They now have an “overweight” rating on the stock.
• 4/24/2026 – Elevance Health was upgraded by Weiss Ratings from “sell (d+)” to “hold (c-)”.
• 4/24/2026 – Elevance Health had its price target raised by Guggenheim from $396.00 to $399.00. They now have a “buy” rating on the stock.
• 4/24/2026 – Elevance Health had its price target raised by Barclays PLC from $393.00 to $408.00. They now have an “overweight” rating on the stock.
• 4/24/2026 – Elevance Health had its price target raised by The Goldman Sachs Group, Inc. from $350.00 to $370.00. They now have a “neutral” rating on the stock.
• 4/24/2026 – Elevance Health had its price target raised by Sanford C. Bernstein from $384.00 to $424.00. They now have an “outperform” rating on the stock.
• 4/23/2026 – Elevance Health was given a new $364.00 price target by Leerink Partners.
• 4/23/2026 – Elevance Health had its price target raised by Deutsche Bank Aktiengesellschaft from $332.00 to $363.00. They now have a “hold” rating on the stock.
• 4/23/2026 – Elevance Health had its price target raised by Evercore Inc from $345.00 to $360.00.
• 4/23/2026 – Elevance Health had its price target raised by Robert W. Baird from $317.00 to $331.00. They now have a “neutral” rating on the stock.
• 4/20/2026 – Elevance Health had its price target lowered by Jefferies Financial Group Inc. from $395.00 to $391.00. They now have a “buy” rating on the stock.
• 4/15/2026 – Elevance Health had its price target lowered by Robert W. Baird from $340.00 to $317.00. They now have a “neutral” rating on the stock.
• 4/13/2026 – Elevance Health had its price target lowered by Truist Financial Corporation from $390.00 to $375.00. They now have a “buy” rating on the stock.
• 4/8/2026 – Elevance Health is now covered by Evercore Inc. They set a “hold” rating and a $345.00 price target on the stock.
• 3/11/2026 – Elevance Health had its price target lowered by Mizuho from $413.00 to $350.00. They now have an “outperform” rating on the stock.

Elevance Health Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Thursday, June 25th. Stockholders of record on Wednesday, June 10th will be given a dividend of $1.72 per share. This represents a $6.88 annualized dividend and a dividend yield of 1.8%. The ex-dividend date is Wednesday, June 10th. Elevance Health’s payout ratio is 29.26%.

Elevance Health, Inc (NYSE: ELV) is a large U.S.-based health benefits company that provides a broad range of health insurance products and related services. Headquartered in Indianapolis, the company rebranded from Anthem, Inc to Elevance Health in 2022 while continuing to operate consumer-facing health plans under established state and national brands. Gail Boudreaux serves as chief executive officer and president, leading the company’s strategic focus on integrated health care and benefit delivery.

Elevance’s core activities include offering medical and specialty health plans for individuals, employers and government programs, including Medicare and Medicaid managed-care products.